Exelixis

Exelixis doubles down on ADCs for cancer with NBE, Catalent deals

https://pharmaphorum.com/news/exelixis-doubles-down-on-adcs-for-cancer-with-nbe-catalent-deals/

BMS gets an important win for Opdivo combination in kidney cancer

https://pharmaphorum.com/news/bms-gets-an-important-win-for-opdivo-combination-in-kidney-cancer/

Exelixis’ Cabometyx approved in second-line liver cancer in US

https://pharmaphorum.com/news/exelixis-cabometyx-approved-in-second-line-liver-cancer-in-us/

Ipsen/Exelixis’ drug approved in EU for kidney cancer

https://pharmaphorum.com/news/ipsenexelixis-drug-approved-eu-kidney-cancer/

Close in 10 seconds

Pharmaphorum.com

Search